Stem cell therapies targeting key immune cells, such as T cells and NK cells, have been developed to facilitate a variety of disease treatment. To illustrate the mechanism of action for inducible pluripotent stem cells (iPSCs)-derived NK cell therapy, Creative Biolabs has established a panel of functional assays for effectively generating iPSC-derived NK cells and investigating their potency in disease therapy.
iPSCs have been considered as an effective strategy for developing novel stem cell therapies against various types of human diseases. Previous studies have demonstrated that iPSCs can be differentiated to tumor-specific natural killer (NK) cells and T cells. Among them, iPSCs-derived NK cells have shown promising results in identifying and destroying infected or malignant cells in different diseases. Meanwhile, the HLA-independent cytotoxic capacity of iPSCs-derived NK cells has also proven its potential for generating new cell immunotherapies against diseases, especially for tumors. Furthermore, recent researchers have indicated that these iPSCs-derived NK cells can prevent tumor progression and improve the overall survival of ovarian patients. Additionally, a number of markers, such as CD16, NKG2D, TRAIL, and CD56, have been confirmed in the process of functional NK cell generation from iPSCs. As a consequence, iPSC-derived NK cells have established the foundation for the next generation of stem cell therapy.
Fig.1 Custom iPSC-derived NK Cell Services.
iPSC-based cell therapy is a valuable tool for treating both malignant and non-malignant human diseases. So far, many attempts have been made to harness iPSC-derived NK cells with the purpose to provide cell therapies for patients suffered from different cancers. Currently, Creative Biolabs offers a series of custom iPSC-derived NK cell services to help our clients generate NK cells from iPSCs for future cell therapy applications. Our iPSC-derived NK cell product is stable both in vitro and in vivo assays, which can be broadly used as a new model to study iPSC-derived NK cell functions and NK cell-related diseases. For instance, recent studies conducted by our labs have used a novel culture system to efficiently generate NK cells from human iPSC without cell sorting and xenogeneic stromal cells. In addition, we have also developed several platforms to assess the high reprogramming efficacy of these NK cells.
Fig.2 Human iPSC-derived NK cells provide an 'off-the-shelf' resource for cancer therapy. 1
Our custom iPSC-derived NK cell service offers a unique and specialized solution for biotechnology companies looking to study or utilize NK cells in their research. By generating iPSC-derived NK cells, we are able to provide a consistent and scalable source of these powerful immune cells for a variety of applications. The customized nature of our service allows biotechnology companies to tailor the iPSC-derived NK cells to their specific research needs. This can include
By leveraging the capabilities of iPSC technology, we offer a cutting-edge solution that enables innovative research in the field of immune cell biology.
As a world-leading service provider of iPSC-derived cell services, Creative Biolabs has accumulated extensive experience from the accomplishment of different projects, during which we have received a lot of recognition and praise from our clients. We are very proud of providing high-quality, omnidirectional assays to our valued clients to remove the difficulties of your projects. For more details on iPSC services we can provide to your project, please feel free to contact us or send us an inquiry.
Below are the findings presented in the article related to ipsc-derived NK cells.
Cichocki et al. developed a method for manufacturing NK cells from iPSC. These manufactured NK cells produce inflammatory cytokines that kill tumor cells and effectively synergize with antitumor T cells in vitro and in mouse models, supporting their potential as an off-the-shelf anticancer treatment.
Their data demonstrated that iPSC-derived NK cells (iNK) are highly functional and have a broad spectrum of cytotoxic activity against hematological and solid tumors. iNK cells recruit CD4+ and CD8+ T cells, enabling them to respond to PD-1 blockade, thereby enhancing inflammatory cytokine secretion and tumor lysis.
Fig. 3 iNK cells are functional against multiple hematopoietic and solid tumor cell lines.2
References
For Research Use Only. Not For Clinical Use.
